Peptide Cancer Vaccine Market Size, Share, Growth, and Industry Growth by Type (Multivalent peptide vaccine, Peptide cocktail type, Personalized peptide vaccine, Peptide-pulsed dendritic cancer vaccine, Hybrid peptide vaccine and Others) By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others) Regional Forecast To 2031

Updated On: 01 April 2024

Peptide Cancer Vaccine Market Report Overview

• 

•  Request a Free Sample to learn more about this report

The global peptide cancer vaccine market size is expected to be USD 0.56435 billion in 2022. The market is projected to touch USD 4.71 billion in 2031, exhibiting a CAGR of 24.27% during the forecast period.

The sudden spike in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.The global COVID-19 pandemic has been unprecedented and staggering, with peptide cancer vaccine experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels.

Cancer-specific T lymphocytes with the ability to regulate or eradicate tumors can be stimulated and grown by peptide cancer vaccines. One or more short or long amino acid sequences acting as tumor antigens are included in the vaccination, together with a vaccine adjuvant. Recent clinical trial findings utilizing peptide cancer vaccines had demonstrated unfavorable effects. Therefore, peptide vaccine experts deemed this therapy to be out of date and said it was no longer an option for treating cancer. This method of treating malignant illnesses has, however, come back into use as a result of advances in our knowledge of the crucial roles that immunological adjuvants, delivery systems for vaccines, and T cell dynamics play in disease.

COVID-19 Impact: Negative Impact on Supply Chains, Productions and Delivery Times to Impede the Market

Lockdowns, travel restrictions, and business closures brought on by the COVID-19 have a negative impact on the economies and industries of many different nations. Numerous factories and plants have been shut down, which has had a negative impact on global supply chains, production, delivery times, and product sales on the international market. Several companies had already made announcements about potential product delivery delays and a decline in future sales. The report evaluates the COVID-19 pandemic's effects both now and in the future on the market as a whole, providing more accurate and reliable projections in light of the current market situation. The opportunities for business partnerships and collaborations are also being impacted by the global travel restrictions put in place by nations in Europe, Asia, and North America.

LATEST TRENDS

"Growing Need for Immunotherapy Based Treatments to Augment the Market"

As a result of the advantages, producers are concentrating their efforts on research to develop peptide cancer vaccines. The medical treatment known as "biological response modifiers" includes cancer vaccinations. There is a growing need for novel immunotherapy-based treatments due to the incidence of chronic illnesses like cancer rising and the ineffectiveness of existing treatments for the condition. Dendritic cell vaccines, monoclonal immunotherapy, antibody-drug conjugates, and peptide-based cancer vaccines are some of the several forms of immunotherapy. Due to the product's user-friendliness, simple production method, and successful mechanism, peptide cancer vaccines are often used.

Peptide Cancer Vaccine Market Segmentation

• 

•  Request a Free Sample to learn more about this report

• By Type Analysis

By type, market is segmented into multivalent peptide vaccine, peptide cocktail type, personalized peptide vaccine, peptide-pulsed dendritic cancer vaccine, hybrid peptide vaccine and others. The multivalent peptide vaccine segment will dominate the market in the coming years.

• By Application Analysis

Based on applications, the market is classified into Breast cancer, lung cancer, melanoma, prostate cancer and others. The breast cancer segment will lead the global share through 2031.

DRIVING FACTORS

"Treatment of Solid Tumors and Clinical Trials to Propel the Market Growth"

Because of its effective mechanism, straightforward manufacturing process, and approachable nature, the peptide-based cancer vaccine is the one that is most commonly used. For the treatment of solid tumors and in clinical trials, peptide cancer vaccines are used. When a tumor in the body is exposed to a peptide cancer vaccine, it triggers a T-cell immune response, or it increases pre-existing immunity to the tumor. Tumor-specific T lymphocytes can control or eradicate tumors by inducing and growing in response to peptide cancer vaccines. Clinical trials using peptide cancer vaccines have recently produced unsatisfactory results. Researchers studying peptide vaccines have therefore declared this therapy to be no longer relevant and technically impractical for the treatment of cancer.

"Numerous Advantage Over Traditional Cancer Treatments to Boost the Market"

Due to the numerous advantages peptide therapeutics have over traditional cancer treatments, the market for them is currently booming. The reduced toxicity of peptides can be attributed to both their ease of disintegration into their individual amino acid residues and their low propensity to interact with molecules other than their target molecules. Furthermore, a lot of pharmaceutical corporations have become interested in them due to how easily they can be produced. Researchers working on new peptides that target cancer receptors have also become interested in these molecules due to their exceptional capacity to cross the blood-brain barrier. Due to several favorable factors, including their high specificity, expanding drug discovery investments, and rising cancer incidence rates, the global market for peptide cancer vaccines is anticipated to expand in the upcoming years.

RESTRAINING FACTORS

"Requirement od Specialized Transport and Storage to Hinder the Market"

The market's expansion will be constrained by a number of limitations. The lack of cancer vaccinations in distant areas and the requirement for specialized transport and storage are obstacles to the overall growth of the worldwide peptide cancer vaccine business. According to predictions, enzyme degradation and a lack of knowledge about peptides will hinder the market. It is difficult to rationally create peptide-based vaccines that effectively thwart and treat the growth of cancer cells. The complexity of the interconnected relationships is impossible to foresee. In vivo, the presence of nearby molecules makes things more difficult and causes decreased biological activity as well as undesirable side effects. Another obstacle that needs to be overcome is getting peptide-based vaccines into cells for targeted delivery to effector cells.

During the projected period, it is anticipated that the high cost of cancer treatment would impede market expansion.

Peptide Cancer Vaccine Market Regional Insights

• 

•  Request a Free Sample to learn more about this report

"North America to Grow Exponentially Over the Forecast Period"

The market for peptide cancer vaccines was dominated by North America, with Europe coming in second. The presence of several leading pharmaceutical and biotech firms in this area, including Pfizer, Inc., Novartis, Merck, GlaxoSmithKline, and Roche, is responsible for this. A further factor that is anticipated to support market expansion is the rising incidence of cancer. The National Cancer Institute estimates that in the U.S., there were approximately as many new cases of cancer diagnosed as there were cancer deaths. It's anticipated that there will be more cancer patients.

Additionally, a number of pharmaceutical and biotech firms are concentrating on developing their presence in the Asia Pacific region and carrying out R&D operations in order to provide patients with easier access to clinical trials and low-cost operational savings. The global market for peptide cancer vaccines in Asia Pacific is growing as a result of rising government investment in R&D.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Market Players Profiled

• Imugene (Australia)
• Generex Biotechnology (Canada)
• BrightPath Biotherapeutics (Japan)
• Sellas (U.S.)
• TapImmune (U.S.)
• OncoTherapy Science (Japan)
• VAXON Biotech (France)
• Boston Biomedical (U.S.)
• Ultimovacs (Norway)
• Immatics (Germany)
• ISA Pharmaceuticals (Netherlands)

REPORT COVERAGE

The market research study examines the worldwide market in detail, focusing on important elements such as leading players, product/services or type, and leading end-use applications. Aside from that, the research analyses major advancements and provides insights into lighting market trends. In addition to the causes indicated above, the paper includes a number of other factors that have contributed to recent growth.